These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24295059)

  • 1. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
    de Nijs T; Sniderman A; de Graaf J
    Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
    Farnier M; Chen E; Johnson-Levonas AO; McCrary Sisk C; Mitchel YB
    Vasc Health Risk Manag; 2014; 10():279-90. PubMed ID: 24855368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
    Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
    J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.
    Thanassoulis G; Williams K; Ye K; Brook R; Couture P; Lawler PR; de Graaf J; Furberg CD; Sniderman A
    J Am Heart Assoc; 2014 Apr; 3(2):e000759. PubMed ID: 24732920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What is a good marker for serum cholesterol to identify high-risk patients at general health checks?].
    Fujioka Y
    Rinsho Byori; 2012 Apr; 60(4):328-35. PubMed ID: 22686042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
    Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
    J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
    Andrikoula M; McDowell IF
    Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
    Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
    Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
    Robinson JG; Wang S; Jacobson TA
    Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the detection and treatment of atherogenic low-density lipoproteins.
    Sniderman A; Kwiterovich PO
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.